CN116179646A - 一种***炎多联检试剂盒 - Google Patents
一种***炎多联检试剂盒 Download PDFInfo
- Publication number
- CN116179646A CN116179646A CN202211611774.9A CN202211611774A CN116179646A CN 116179646 A CN116179646 A CN 116179646A CN 202211611774 A CN202211611774 A CN 202211611774A CN 116179646 A CN116179646 A CN 116179646A
- Authority
- CN
- China
- Prior art keywords
- reaction
- reaction hole
- hole
- kit
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010046914 Vaginal infection Diseases 0.000 title claims abstract description 38
- 238000007689 inspection Methods 0.000 title description 3
- 238000006243 chemical reaction Methods 0.000 claims abstract description 148
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims abstract description 76
- 102100032126 Aminopeptidase B Human genes 0.000 claims abstract description 27
- 108090000449 aminopeptidase B Proteins 0.000 claims abstract description 27
- 108010056771 Glucosidases Proteins 0.000 claims abstract description 17
- 102000004366 Glucosidases Human genes 0.000 claims abstract description 17
- 108010065152 Coagulase Proteins 0.000 claims abstract description 15
- 102100034560 Cytosol aminopeptidase Human genes 0.000 claims abstract description 14
- 102000005348 Neuraminidase Human genes 0.000 claims abstract description 14
- 108010006232 Neuraminidase Proteins 0.000 claims abstract description 14
- 108010017378 prolyl aminopeptidase Proteins 0.000 claims abstract description 14
- 108010000849 leukocyte esterase Proteins 0.000 claims abstract description 9
- 239000000243 solution Substances 0.000 claims description 44
- 239000000758 substrate Substances 0.000 claims description 30
- 239000003153 chemical reaction reagent Substances 0.000 claims description 25
- 201000008100 Vaginitis Diseases 0.000 claims description 21
- 239000007979 citrate buffer Substances 0.000 claims description 17
- 239000007788 liquid Substances 0.000 claims description 15
- 239000003381 stabilizer Substances 0.000 claims description 15
- RLFWWDJHLFCNIJ-UHFFFAOYSA-N 4-aminoantipyrine Chemical compound CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 claims description 14
- 239000007853 buffer solution Substances 0.000 claims description 13
- 239000002904 solvent Substances 0.000 claims description 13
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- 239000003085 diluting agent Substances 0.000 claims description 9
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 8
- 229930064664 L-arginine Natural products 0.000 claims description 8
- 235000014852 L-arginine Nutrition 0.000 claims description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- 239000012089 stop solution Substances 0.000 claims description 8
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 7
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 7
- 102000003992 Peroxidases Human genes 0.000 claims description 7
- 229930182478 glucoside Natural products 0.000 claims description 7
- 150000008131 glucosides Chemical class 0.000 claims description 7
- 108040007629 peroxidase activity proteins Proteins 0.000 claims description 7
- 229960002920 sorbitol Drugs 0.000 claims description 7
- 235000010323 ascorbic acid Nutrition 0.000 claims description 6
- 229960005070 ascorbic acid Drugs 0.000 claims description 6
- 239000011668 ascorbic acid Substances 0.000 claims description 6
- IHUKVJKKTBLTEE-QMMMGPOBSA-N (2s)-2-acetamido-5-[[amino-(methylcarbamoylamino)methylidene]amino]-n-methylpentanamide Chemical compound CNC(=O)NC(N)=NCCC[C@H](NC(C)=O)C(=O)NC IHUKVJKKTBLTEE-QMMMGPOBSA-N 0.000 claims description 5
- MJZNUFVVBKAGQE-UHFFFAOYSA-N 2-(5-bromo-4-chloro-1h-indol-3-yl)acetic acid Chemical compound C1=C(Br)C(Cl)=C2C(CC(=O)O)=CNC2=C1 MJZNUFVVBKAGQE-UHFFFAOYSA-N 0.000 claims description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 5
- 229930195725 Mannitol Natural products 0.000 claims description 5
- 230000002378 acidificating effect Effects 0.000 claims description 5
- 239000000594 mannitol Substances 0.000 claims description 5
- 235000010355 mannitol Nutrition 0.000 claims description 5
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical group [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims description 5
- 229940001584 sodium metabisulfite Drugs 0.000 claims description 5
- 235000010262 sodium metabisulphite Nutrition 0.000 claims description 5
- FRPHFZCDPYBUAU-UHFFFAOYSA-N Bromocresolgreen Chemical compound CC1=C(Br)C(O)=C(Br)C=C1C1(C=2C(=C(Br)C(O)=C(Br)C=2)C)C2=CC=CC=C2S(=O)(=O)O1 FRPHFZCDPYBUAU-UHFFFAOYSA-N 0.000 claims description 4
- 108090000371 Esterases Proteins 0.000 claims description 4
- -1 L-arginine-beta-naphthylamine hydrochloride Chemical group 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 239000003223 protective agent Substances 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- RUKJCCIJLIMGEP-ONEGZZNKSA-N 4-dimethylaminocinnamaldehyde Chemical compound CN(C)C1=CC=C(\C=C\C=O)C=C1 RUKJCCIJLIMGEP-ONEGZZNKSA-N 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Substances OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 239000003593 chromogenic compound Substances 0.000 claims description 2
- 238000007837 multiplex assay Methods 0.000 claims 8
- 230000001681 protective effect Effects 0.000 claims 1
- 238000001514 detection method Methods 0.000 abstract description 33
- 230000035945 sensitivity Effects 0.000 abstract description 7
- 210000001215 vagina Anatomy 0.000 abstract description 7
- 244000052616 bacterial pathogen Species 0.000 abstract description 6
- 208000015181 infectious disease Diseases 0.000 abstract description 6
- 208000003322 Coinfection Diseases 0.000 abstract description 5
- 208000035473 Communicable disease Diseases 0.000 abstract description 2
- 208000004926 Bacterial Vaginosis Diseases 0.000 description 9
- 208000034164 Cytolytic vaginosis Diseases 0.000 description 9
- 208000037009 Vaginitis bacterial Diseases 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 208000007074 Trichomonas Vaginitis Diseases 0.000 description 6
- 208000025206 Trichomonas vaginitis urogenital infection Diseases 0.000 description 6
- 108010055851 Acetylglucosaminidase Proteins 0.000 description 5
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 4
- 238000003794 Gram staining Methods 0.000 description 4
- 210000003756 cervix mucus Anatomy 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 3
- 201000007096 Vulvovaginal Candidiasis Diseases 0.000 description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 3
- 238000000386 microscopy Methods 0.000 description 3
- 238000003908 quality control method Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- CPEHFPYZJQRWHM-PXUHCLMOSA-N (4R,5R,6S)-5-amino-5-bromo-4-chloro-2,4-dihydroxy-3-(1H-indol-2-yl)-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid Chemical class Br[C@]1([C@](C(C(C(O)=O)(O)O[C@H]1[C@H](O)[C@H](O)CO)C=1NC2=CC=CC=C2C=1)(O)Cl)N CPEHFPYZJQRWHM-PXUHCLMOSA-N 0.000 description 2
- CERZMXAJYMMUDR-QBTAGHCHSA-N 5-amino-3,5-dideoxy-D-glycero-D-galacto-non-2-ulopyranosonic acid Chemical class N[C@@H]1[C@@H](O)CC(O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO CERZMXAJYMMUDR-QBTAGHCHSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 238000009007 Diagnostic Kit Methods 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 241001148470 aerobic bacillus Species 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000012470 diluted sample Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- QJWQYOHBMUQHGZ-UHFFFAOYSA-N ethanol;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound CCO.OC(=O)CC(O)(C(O)=O)CC(O)=O QJWQYOHBMUQHGZ-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- ZXWHANCSQZVZCM-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;methanol Chemical compound OC.OC(=O)CC(O)(C(O)=O)CC(O)=O ZXWHANCSQZVZCM-UHFFFAOYSA-N 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 208000001387 Causalgia Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 208000008350 Pruritus Vulvae Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 208000005448 Trichomonas Infections Diseases 0.000 description 1
- 241000224527 Trichomonas vaginalis Species 0.000 description 1
- 206010056530 Vulvovaginal pruritus Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000003464 asthenopia Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 229940078916 carbamide peroxide Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- AQLJVWUFPCUVLO-UHFFFAOYSA-N urea hydrogen peroxide Chemical compound OO.NC(N)=O AQLJVWUFPCUVLO-UHFFFAOYSA-N 0.000 description 1
- 208000013464 vaginal disease Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
- C12Q1/28—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving peroxidase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2326/00—Chromogens for determinations of oxidoreductase enzymes
- C12Q2326/90—Developer
- C12Q2326/96—4-Amino-antipyrine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/902—Oxidoreductases (1.)
- G01N2333/908—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/974—Thrombin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明公开了一种***炎多联检试剂盒,包括具有多个反应孔的反应板,反应孔包含过氧化氢反应孔、精氨酸氨基肽酶反应孔、凝固酶反应孔、脯氨酸氨基肽酶反应孔、唾液酸苷酶反应孔、乙酰氨基葡萄糖苷酶反应孔、高浓度过氧化氢反应孔、pH反应孔、白细胞酯酶反应孔和葡萄糖苷酶反应孔。本发明试剂盒中的精氨酸氨基肽酶与过氧化氢相结合,可确定样本中是否存在需氧菌性***炎,提高了需氧菌性***炎的灵敏性和准确性;本发明通过致病菌感染情况区分BV、VVC、TV、AV和CV五种***感染性疾病,适用于临床上***混合感染样本的快速检测,多个指标相互结合确定致病菌,避免单独观察单一指标产生的片面性和干扰因素,提高检测结果的可靠性。
Description
技术领域
本发明涉及体外诊断试剂领域,尤其是涉及一种***炎多联检试剂盒。
背景技术
***是女性下生殖道免疫防御***的第一道屏障,是生理性开放的器官,健康育龄期女性***微环境是由以乳杆菌为优势菌群,多种厌氧菌及需氧菌共同组成的微生态动态平衡***,其中乳杆菌通过分解糖原产生乳酸、过氧化氢等多种机制抑制其他细菌的过度繁殖,在***自净、维持女性***健康状态中起关键作用。然而,这种微生态平衡***受外界因素很容易被打破,如药物、吸烟、机体免疫状态和***等因素。女性的***微生态平衡***一旦被打破,将会引起致病菌的过度繁殖,进而引起各种***疾病,主要表现为***分泌物异常、外阴瘙痒灼痛等症状。
常见的***感染性疾病主要包括细菌性***病(BV)、霉菌性***炎(VVC)(又称外阴***假丝酵母菌)、滴虫性***炎(TV)、需氧菌性***炎(AV)、细胞溶解性***病(CV)。目前,***感染常用的检测方法和技术手段为显微镜镜检和干化学酶法诊断试剂。其中,显微镜镜检虽然具有较好的特异性,但该检测方式主观性比较强,容易漏检,且长时间观察也容易引起视觉疲劳。因而,目前大多采用以基于干化学酶法的诊断试剂盒来进行检测。现有的干化学酶法诊断试剂盒大多数只能检测细菌性***病、霉菌性***炎(外阴***假丝酵母菌引起的***炎)和***毛滴虫病;极少数试剂盒可以检测需氧菌性***炎,但即便能检测,结果的可靠性比较差;另外,现今没有干化学酶法试剂可以检测细胞溶解性***病,进而导致出现严重的漏检情况。
发明内容
鉴于此,本发明提供了一种***炎多联检试剂盒,不仅具有较高的灵敏度、特异性和稳定性,提高了检测结果的准确性和可靠性,还能精准区分BV、VVC、TV、AV和CV,适用于***感染的快速检测,具有很大的推广价值。
为实现上述目的,本发明采取下述技术方案:
本发明所述的***炎多联检试剂盒,包括具有多个反应孔的反应板,所述反应孔依次为过氧化氢反应孔、精氨酸氨基肽酶反应孔、凝固酶反应孔、脯氨酸氨基肽酶反应孔、唾液酸苷酶反应孔、乙酰氨基葡萄糖苷酶反应孔、高浓度过氧化氢反应孔、pH反应孔、白细胞酯酶反应孔和葡萄糖苷酶反应孔;
所述过氧化氢反应孔的稳定保护剂为抗坏血酸;
所述高浓度过氧化氢孔的稳定保护剂为焦亚硫酸钠;
所述精氨酸氨基肽酶反应孔的显色底物为含有色原的L-精氨酸单肽底物。
在上述方案中,抗坏血酸的浓度优选为5-50mg/L,溶剂为PBS缓冲液;焦亚硫酸钠的浓度为0.03-0.2g/L,溶剂为柠檬酸盐缓冲液。
在本发明中,含有色原的L-精氨酸单肽底物的浓度为0.2-0.8g/L,溶剂为Tris-柠檬酸缓冲液;所述精氨酸氨基肽酶反应孔的稳定剂保护液为30-50g/L蔗糖。所述精氨酸氨基肽酶反应孔的检测限浓度为7 U/mL,该反应孔可与过氧化氢氧化孔结合来判读需氧菌性***炎。
在本发明中,含有色原的L-精氨酸单肽底物优选为L-精氨酸-β-萘胺盐酸盐。
在本发明中,所述试剂盒还包括稀释液和用于终止精氨酸氨基肽酶反应孔、脯氨酸氨基肽酶反应孔和凝固酶反应孔反应的终止液,所述稀释液为含有甘露醇浓度为0.1%~3%的0.9%氯化钠溶液。采用含有甘露醇的0.9%氯化钠溶液作为样本稀释液,有效提高显色结果的可读性,进而提高检测结果的可靠性。
在本发明中,所述终止液为酸性终止液。更优选的,所述酸性终止液为含有0.01%-0.2% 4-二甲氨基肉桂醛的盐酸,且所述盐酸的浓度为0.5~2.0M。
更优选的,所述过氧化氢反应孔包被的反应底物还包括过氧化物酶50-200kU/L、4-氨基安替比林0.3-1g/L,TOOS 1-4g/L,溶剂为PBS缓冲液;
所述高浓度过氧化氢反应孔包被的反应底物还包括过氧化物酶50-200kU/L、4-氨基安替比林0.3-1g/L,TOOS 1-4g/L,溶剂为柠檬酸盐缓冲液。
在本发明中,所述唾液酸苷酶反应孔的底物反应试剂为含有色原的神经氨酸盐,所述含有色原的神经氨酸盐的配制溶剂是由无水乙醇和柠檬酸盐缓冲液混合而成;其中,在实际配制时无水乙醇和柠檬酸盐缓冲液的体积比优选为1:1;
所述葡萄糖苷酶反应孔的底物反应试剂为浓度为含有色原的葡萄糖苷,所述含有色原的葡萄糖苷采用PBS缓冲液配制而成;
所述pH反应孔的底物反应试剂为溴甲酚绿和 NaOH;其中,溴甲酚绿的浓度优选为0.05-1.5g/L,NaOH溶液的浓度优选为0.05mol/L;
所述白细胞酯酶反应孔的底物反应试剂为5-溴-4-氯-3-吲哚乙酸盐溶液,其中5-溴-4-氯-3-吲哚乙酸盐溶液的溶剂为甲醇和柠檬酸盐缓冲液混合而成,甲醇和柠檬酸盐缓冲液的体积比优选为1:1;
其中,唾液酸苷酶反应孔、葡萄糖苷酶反应孔、pH反应孔和白细胞酯酶反应孔的稳定剂保护液均为20-50g/L D-山梨醇水溶液。
与现有技术相比,本发明的试剂盒具有以下优点:
本发明试剂盒中的精氨酸氨基肽酶与过氧化氢相结合,能够确定样本中是否存在需氧菌,极大地提高了需氧菌性***炎的灵敏性和准确性;并且本发明通过精氨酸氨基肽酶反应孔和过氧化氢反应孔的颜色变化情况判断,结果直观,不需要经验,且结果客观可重复。
本发明的高浓度过氧化氢反应孔和pH反应孔相结合,能够确定样本中的过氧化氢浓度和pH,极大地提高了细胞溶解性***病的灵敏性和准确性;另外,通过显示结果进行判读,结果直观,结果客观可重复。
本发明能同时检测样本中的过氧化氢、精氨酸氨基肽酶、凝固酶、脯氨酸氨基肽酶、唾液酸苷酶、乙酰氨基葡萄糖苷酶、高浓度过氧化氢、pH、白细胞酯酶和葡萄糖苷酶,可以准确确定样本中的致病菌,进而可通过致病菌感染情况区分细菌性***病、霉菌性***炎、滴虫性***炎、需氧菌性***炎、细胞溶解性***病,特别适用于临床上***混合感染样本的快速检测。本发明试剂盒中的多个指标相互结合确定致病菌,避免了单独观察单一指标产生的片面性和干扰因素,提高了检测结果的可靠性。
本发明试剂盒操作简单且具有较高的灵敏度、特异性和稳定性,能实现***混合感染样本的快速联检并将检测结果控制在5min以内,不仅适用于医院,也适用于居家使用,具有很大的推广价值。
具体实施方式
下面通过具体实施例对本发明做更加详细的说明,以便于本领域技术人员的理解。需要说明的是,如无特殊说明,本发明所用的试剂均为可以购买得到的常规试剂,采用的仪器和方法也为本领域常规仪器和方法。另外,稳定剂保护液D-山梨醇溶液、蔗糖溶液、D-半乳糖溶液和海藻糖溶液均是采用蒸馏水配制而成。
实施例1 本发明所述的***炎多联检试剂盒
本发明的***炎多联检试剂盒,包括反应板、终止液和稀释液,反应板具有十个反应孔,十个反应孔分别为过氧化氢反应孔、精氨酸氨基肽酶反应孔、凝固酶反应孔、脯氨酸氨基肽酶反应孔、唾液酸苷酶反应孔、乙酰氨基葡萄糖苷酶反应孔、高浓度过氧化氢反应孔、pH反应孔、白细胞酯酶反应孔和葡萄糖苷酶反应孔。
具体地,过氧化氢反应孔内包被的底物试剂是含过氧化物酶50-200kU/L、4-氨基安替比林0.3-1g/L和TOOS 1-4g/L的PBS缓冲液;该反应孔的稳定剂保护液是抗坏血酸的PBS缓冲液,抗坏血酸的浓度为5-50mg/L。
高浓度过氧化氢反应孔内包被的底物试剂是采用柠檬酸盐缓冲液(pH为5-7、浓度为0.1-0.5 M)、过氧化物酶、4-氨基安替比林和TOOS配制而成,其中过氧化物酶的浓度为50-200kU/L、4-氨基安替比林的浓度为0.3-1g/L,TOOS的浓度为1-4g/L;该反应孔的稳定剂保护液是焦亚硫酸钠0.03-0.2g/L,溶剂为柠檬酸盐缓冲液,该反应孔可用于过氧化氢浓度≥10mg/L的高浓度样本。
精氨酸氨基肽酶反应孔内包被的底物试剂为含有色原的L-精氨酸单肽底物。其中在本实施例中含有色原的L-精氨酸单肽底物优选浓度为0.2-0.8g/L的L-精氨酸-β-萘胺盐酸盐溶液,其采用Tris-柠檬酸缓冲液(浓度为0.1-0.5mol/L,pH为6.0-8.5)配制而成;该反应孔的稳定剂保护液为30-50g/L蔗糖溶液。
pH反应孔内包括的底物试剂是包括溴甲酚绿0.05-1.5g/L和0.05mol/L NaOH(采用蒸馏水配制而成);该反应孔的稳定剂保护液为20-50g/L D-山梨醇。
凝固酶反应孔内包被的底物试剂为浓度为2-10g/L的L-甘氨酸-精氨酸-β-萘胺盐酸盐,由柠檬酸盐缓冲液(浓度为0.1-0.5 M,pH=3.0-6.0)配制而成;该反应孔的稳定剂保护液为20-50g/L海藻糖溶液。
脯氨酸氨基肽酶反应孔内包被的底物反应试剂是由Tris-HCl缓冲液(浓度为0.1-0.5mol/L,pH为6.0-8.5)配制而成的 L-脯氨酸-β-萘胺盐酸盐,浓度为0.2-2 g/L;该反应孔的稳定剂保护液为20-50 g/L海藻糖溶液。
唾液酸苷酶反应孔内包被的底物试剂为含有色原的神经氨酸盐。其中,在本实施例中含有色原的神经氨酸盐优选浓度为0.15-3g/L的5-溴-4-氯-3-吲哚神经氨酸盐(当然,5-溴-4-氯-3-吲哚神经氨酸盐也可以替换为其它含有色原的神经氨酸盐),该底物试剂是采用乙醇-柠檬酸盐缓冲溶液配制而成,其中,乙醇-柠檬酸盐缓冲溶液的体积比为1:1,柠檬酸盐溶液的浓度为0.1-0.5M,pH为4.0-6.0 ;该反应孔的稳定剂保护液为20-50g/L D-山梨醇溶液。
乙酰氨基葡萄糖苷酶反应孔内包被的反应试剂是浓度为0.2-2g/L的6-氯-3-吲哚-2-乙酰氨基-2-脱氧基-β-D-葡萄糖苷,采用PBS缓冲液(浓度为0.1-0.5 M,pH为4.0-6.0)配制而成;该反应孔的稳定剂保护液为20-50g/L D-半乳糖。
白细胞酯酶反应孔内包被的底物试剂为浓度为0.1-6g/L的5-溴-4-氯-3-吲哚乙酸盐,是采用甲醇-柠檬酸盐缓冲溶液(甲醇和柠檬酸盐缓冲溶液的体积比为1:1,柠檬酸盐缓冲溶液的浓度为0.1-0.5M,pH为5.0-7.0)配制而成;该反应孔的稳定剂保护液为20-50g/L D-山梨醇溶液。
葡萄糖苷酶反应孔内包被的底物反应试剂为含有色原的葡萄糖苷。其中,在本实施例中含有色原的葡萄糖苷优选浓度为0.5-3g/L的6-氯-3-吲哚-a-D-葡萄糖苷溶液(当然,6-氯-3-吲哚-a-D-葡萄糖苷也可替换为其它含有色原的葡萄糖苷),其采用PBS缓冲液(浓度为0.1-0.5 M,pH为4.0-6.0)配制而成;该反应孔的稳定剂保护液为20-50g/L D-山梨醇溶液。
稀释液(封装在试剂瓶内)用于涮洗***分泌物拭子,该稀释液为含有甘露醇的0.9%氯化钠溶液,甘露醇的浓度为0.1%~3%(质量百分数)。
在检测时,精氨酸氨基肽酶、脯氨酸氨基肽酶和凝固酶三个指标对应有终止液(封装在试剂瓶内),以提高检测结果的精准性。其中,本发明的终止液为酸性终止液,具体为含有0.01%-0.2%4-二甲氨基肉桂醛(质量分数)的盐酸,盐酸的浓度为0.5~2.0M。
实施例2 本发明试剂盒的使用方法
本发明试剂盒的使用方法,包括以下步骤:
将***分泌物拭子用500 -1000μL稀释液洗脱,得到稀释后的样本;
在每个反应孔内分别滴加30-35μL稀释后的样本,常温或者37℃静置10-20分钟;
静置结束后,向精氨酸氨基肽酶反应孔、脯氨酸氨基肽酶反应孔和凝固酶反应孔内分别加入25 μL酸性终止液终止反应;
根据试剂盒配套的比色卡进行结果判读:
过氧化氢指标:紫色或淡紫色指示阴性;不显色指示阳性;
高浓度过氧化氢指标:正常不显色;红色代表阳性;
pH指标:黄色或绿色说明pH≤4.6,蓝色代表pH≥4.8;
精氨酸氨基肽酶指标:正常不显色或近白色,红色代表阳性;
凝固酶指标:正常不显色或近白色,红色代表阳性;
脯氨酸氨基肽酶:正常不显色或近白色,红色代表阳性;
唾液酶指标:正常不显色或近白色,红色代表阳性;
乙酰氨基葡萄糖苷酶指标:正常不显色,代表阴性;红色代表阳性;
白细胞酯酶指标:正常不显色或为浅蓝色;蓝色代表阳性,提示样本中白细胞≥15个/HP视野,且白细胞越多蓝色越深;
葡萄糖苷酶指标:正常不显色;红色代表阳性。
在上述指标中,脯氨酸氨基肽酶和唾液酸苷酶中的一种或两种阳性,表示细菌性***病感染;凝固酶和葡萄糖苷酶同时阳性且pH值≤4.6或乙酰氨基葡萄糖苷酶阳性且pH值≤4.6,表示外阴***假丝酵母菌感染;凝固酶和葡萄糖苷酶同时阳性且pH值≥4.8,或乙酰氨基葡萄糖苷酶阳性且pH值≥4.8,表示滴虫感染;精氨酸氨基肽酶阳性且过氧化氢阳性,表示感染需氧菌性***炎;高浓度过氧化氢阳性且pH值≤4.1,表示感染细胞溶解性***病。
本发明的试剂盒具有过氧化氢、精氨酸氨基肽酶、凝固酶、脯氨酸氨基肽酶、唾液酸苷酶、乙酰氨基葡萄糖苷酶、高浓度过氧化氢、pH、白细胞酯酶和葡萄糖苷酶十个指标相结合,不仅能区分细菌性***病BV、霉菌性***炎VVC、滴虫性***炎TV和需氧菌性***炎AV、细胞溶解性***病CV,还能将这些指标相互结合提高检测准确率,避免了单独观察单一指标产生的片面性和干扰因素,提高了临床上***混合感染的检测结果更加准确。
实施例3 本发明试剂盒的检测限
本实施例以精氨酸氨基肽酶为例,确定了每个指标的检测限浓度。具体地,配制不同浓度梯度的精氨酸氨基肽酶质控品,向精氨酸氨基肽酶反应孔内滴加精氨酸氨基肽酶质控品,观察该反应孔的显色变化结果,以确定精氨酸氨基肽酶反应孔的检测限,各反应孔对应的最低显色检测限见表1。
表1 本发明试剂盒的检测限
另外,当过氧化脲浓度为10mg/L及其以上浓度时,过氧化氢指标为阴性,高浓度过氧化氢指标阳性,完全不影响结果判读。
实施例4 本发明试剂盒的特异性
本实施例分别以0.5麦氏大肠杆菌和0.5麦氏金黄色葡萄球菌考察本发明试剂盒中过氧化氢反应孔、凝固酶反应孔、脯氨酸氨基肽酶反应孔、唾液酸苷酶反应孔、乙酰氨基葡萄糖苷酶反应孔、高浓度过氧化氢反应孔、白细胞酯酶反应孔和葡萄糖苷酶反应孔的特异性,用白色念珠菌作为干扰考察本发明试剂盒中精氨酸氨基肽酶反应孔的特异性,结果见表2。
表2 本发明试剂盒的特异性
由上表2可知,本发明试剂盒中的每个反应孔均具有较好的特异性,并且本发明试剂盒在常温存放半年后依然表现出很好的特异性,也说明本发明试剂盒稳定性良好,确保检测结果的精准性,能够满足临床上***混合感染的检测需求。
实施例5 本发明试剂盒的稳定性
本实施例用实施例3得到的检测限质控品作为样本,考察本发明试剂盒的稳定性,结果见表3。
表3 本发明试剂盒的稳定性
由表3可知,本发明试剂盒在常温放置6个月后,各反应孔的显色情况和常温放置0天时的显色结果一致,说明本发明试剂盒中十个反应孔均具有较好的稳定性。另外,结合表2可知,本发明试剂盒在常温放置半年后,各反应孔并不受干扰菌的影响,进一步说明本发明试剂盒具有很好的稳定性。
实施例6 本发明试剂盒的准确率
本发明同时用革兰氏染色显微镜镜检和本发明实施例1制备得到的试剂盒分别对临床上212例***分泌物样本进行对比,结果见表4和表5。
表4 本发明和革兰氏染色显微镜镜检对AV***炎的检测结果
表5 本发明和革兰氏染色显微镜镜检对CV***炎的检测结果
由上表4和表5可知,本发明试剂盒对测需氧菌性***炎(即AV)的灵敏度为84.38%,特异性为95.56%,符合率(即本发明与革兰氏染色显微镜镜检结果的符合率)为93.87%;本发明试剂盒对细胞溶解性***病(即CV)的灵敏度为87.5%,特异性为98.53%,符合率(即本发明与革兰氏染色显微镜镜检结果的符合率)为98.11%。结果表明,本发明具有较好的特异性和准确率。
Claims (8)
1.一种***炎多联检试剂盒,包括具有多个反应孔的反应板,其特征在于:所述反应孔依次为过氧化氢反应孔、精氨酸氨基肽酶反应孔、凝固酶反应孔、脯氨酸氨基肽酶反应孔、唾液酸苷酶反应孔、乙酰氨基葡萄糖苷酶反应孔、高浓度过氧化氢反应孔、pH反应孔、白细胞酯酶反应孔和葡萄糖苷酶反应孔;
所述过氧化氢反应孔的稳定保护剂为抗坏血酸;
所述高浓度过氧化氢孔的稳定保护剂为焦亚硫酸钠;
所述精氨酸氨基肽酶反应孔的显色底物为含有色原的L-精氨酸单肽底物。
2.根据权利要求1所述的***炎多联检试剂盒,其特征在于:所述抗坏血酸的浓度为5-50mg/L;所述焦亚硫酸钠的浓度为0.03-0.2g/L。
3.根据权利要求1所述的***炎多联检试剂盒,其特征在于:所述含有色原的L-精氨酸单肽底物的浓度为0.2-0.8g/L,溶剂为Tris-柠檬酸缓冲液;所述精氨酸氨基肽酶反应孔的稳定剂保护液为30-50g/L蔗糖。
4.根据权利要求3所述的***炎多联检试剂盒,其特征在于:所述含有色原的L-精氨酸单肽底物为L-精氨酸-β-萘胺盐酸盐。
5.根据权利要求1所述的***炎多联检试剂盒,其特征在于:还包括稀释液和用于终止精氨酸氨基肽酶反应孔、脯氨酸氨基肽酶反应孔和凝固酶反应孔反应的终止液,所述稀释液为含有甘露醇浓度为0.1%~3%的0.9%氯化钠溶液;所述终止液为酸性终止液。
6.根据权利要求5所述的***炎多联检试剂盒,其特征在于:所述酸性终止液为含有0.01%-0.2%4-二甲氨基肉桂醛的盐酸,且所述盐酸的浓度为0.5~2.0M。
7.根据权利要求1所述的***炎多联检试剂盒,其特征在于:所述过氧化氢反应孔包被的反应底物还包括过氧化物酶50-200kU/L、4-氨基安替比林0.3-1g/L,TOOS 1-4g/L,溶剂为PBS缓冲液;
所述高浓度过氧化氢反应孔包被的反应底物还包括过氧化物酶50-200kU/L、4-氨基安替比林0.3-1g/L,TOOS 1-4g/L,溶剂为柠檬酸盐缓冲液。
8.根据权利要求1所述的***炎多联检试剂盒,其特征在于:
所述唾液酸苷酶反应孔的底物反应试剂为含有色原的神经氨酸盐,所述含有色原的神经氨酸盐的配制溶剂是由无水乙醇和柠檬酸盐缓冲液混合而成;
所述葡萄糖苷酶反应孔的底物反应试剂为浓度为含有色原的葡萄糖苷,所述含有色原的葡萄糖苷采用PBS缓冲液配制而成;
所述pH反应孔的底物反应试剂为溴甲酚绿和NaOH;
所述白细胞酯酶反应孔的底物反应试剂为5-溴-4-氯-3-吲哚乙酸盐溶液,其中5-溴-4-氯-3-吲哚乙酸盐溶液的溶剂为甲醇和柠檬酸盐缓冲液混合而成;
唾液酸苷酶反应孔、葡萄糖苷酶反应孔、pH反应孔和白细胞酯酶反应孔的稳定剂保护液均为20-50g/L D-山梨醇水溶液。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211611774.9A CN116179646A (zh) | 2022-12-15 | 2022-12-15 | 一种***炎多联检试剂盒 |
CN202311178766.4A CN117004685A (zh) | 2022-12-15 | 2023-09-13 | 一种***炎多联检试剂盒 |
CN202311178769.8A CN117265066A (zh) | 2022-12-15 | 2023-09-13 | 一种***炎多联检试剂盒 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211611774.9A CN116179646A (zh) | 2022-12-15 | 2022-12-15 | 一种***炎多联检试剂盒 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116179646A true CN116179646A (zh) | 2023-05-30 |
Family
ID=86439304
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211611774.9A Pending CN116179646A (zh) | 2022-12-15 | 2022-12-15 | 一种***炎多联检试剂盒 |
CN202311178766.4A Pending CN117004685A (zh) | 2022-12-15 | 2023-09-13 | 一种***炎多联检试剂盒 |
CN202311178769.8A Pending CN117265066A (zh) | 2022-12-15 | 2023-09-13 | 一种***炎多联检试剂盒 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311178766.4A Pending CN117004685A (zh) | 2022-12-15 | 2023-09-13 | 一种***炎多联检试剂盒 |
CN202311178769.8A Pending CN117265066A (zh) | 2022-12-15 | 2023-09-13 | 一种***炎多联检试剂盒 |
Country Status (1)
Country | Link |
---|---|
CN (3) | CN116179646A (zh) |
-
2022
- 2022-12-15 CN CN202211611774.9A patent/CN116179646A/zh active Pending
-
2023
- 2023-09-13 CN CN202311178766.4A patent/CN117004685A/zh active Pending
- 2023-09-13 CN CN202311178769.8A patent/CN117265066A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
CN117004685A (zh) | 2023-11-07 |
CN117265066A (zh) | 2023-12-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5434056A (en) | Method of bacteriological analysis, and medium for the detection of bacteria of the Salmonella genus | |
WO2018001215A1 (zh) | 检测细菌性***病的试剂盒 | |
CN107779494B (zh) | 一种检测感染性***炎的试剂盒及其制备方法 | |
EP0530322B1 (en) | Novel and improved method for determination of e. coli in water | |
JP2831474B2 (ja) | サルモネラ菌の同定法および培地 | |
US7588909B2 (en) | Method for detecting Streptococcus agalactiae using α-glucosidase activity | |
CN105334211B (zh) | 一种同时检测尿液中钠和肌酐的试剂盒 | |
CN113030076B (zh) | 一种***分泌物多联检测试纸、制备方法及其测试方法 | |
CN109212176B (zh) | 一种丙酮酸测定试剂盒及其制备方法和应用 | |
Sheiness et al. | High levels of Gardnerella vaginalis detected with an oligonucleotide probe combined with elevated pH as a diagnostic indicator of bacterial vaginosis | |
US20100279330A1 (en) | Method for detecting and/or identifying clostridium difficile | |
CN111690713A (zh) | 一种***炎八联检试剂盒 | |
CN112710853B (zh) | 一种抗干扰、稳定的血清直接胆红素(酶法)测定试剂盒及其制备方法和应用 | |
US20160177370A1 (en) | Method for detecting streptococcus agalactiae using esterase activity | |
CN116179646A (zh) | 一种***炎多联检试剂盒 | |
JP2001161396A (ja) | 試料中の微生物の識別方法 | |
CN206348340U (zh) | 家庭版***炎六联检装置 | |
JP2001128666A (ja) | 血液またはヘミンを含む色素原指示培地 | |
CN107287275B (zh) | 培养基、包含其的试剂盒、及其应用 | |
FI91888B (fi) | Menetelmä mykoplasmabakteerien laskemiseksi ja toteamiseksi | |
CN109402221B (zh) | 一种细菌性***病的快速检测试剂盒及其制备方法和应用 | |
Sophianopoulos et al. | Two new antisickling agents and the use of amino acid salts | |
KR102096662B1 (ko) | 아시네토박터 바우마니 유사 그람음성세균 선별검사용 시약 및 이를 이용한 아시네토박터 바우마니 유사 그람음성세균 선별검사방법 | |
JONES | A study of the prevalence of hydrogen peroxide generating Lactobacilli in bacterial vaginosis: the determination of H2O2 concentrations generated, in vitro, by isolated strains and the levels found in vaginal secretions of women with and without infection | |
Manoni et al. | Measurement of urine leukocytes by a second generation flow cytometer: application in the diagnosis of acute urinary tract infections in adult patients |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20230530 |
|
WD01 | Invention patent application deemed withdrawn after publication |